Lupin Strikes Deal In Suit Over Generic Lunesta
Under the settlement, Lupin and its subsidiary, Lupin Pharmaceuticals Inc., would be able to sell a generic version of Lunesta by the end of November 2013, approximately two months before the expiration of one of the patents-in-suit, 6,444,673.
If Sunovion receives six months of additional pediatric exclusivity for Lunesta, the licensing agreement would go into effect at the end...
Already a subscriber? Click here to login